会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • NOVEL MONOOXYGENASE VARIANTS
    • 新奥尔良的变化
    • WO2012028709A2
    • 2012-03-08
    • PCT/EP2011/065179
    • 2011-09-02
    • B.R.A.I.N. Biotechnology Research And Information Network AGSCHWANEBERG, UlrichBLANUSA, MilanNIEHAUS, FrankECK, Jürgen
    • SCHWANEBERG, UlrichBLANUSA, MilanNIEHAUS, FrankECK, Jürgen
    • C12N9/02
    • C12Y106/02004C12N9/0042
    • The present invention relates to a nucleic acid molecule encoding a polypeptide having cytochrome P450 monooxygenase activity, wherein said polypeptide comprises a reductase domain that deviates by at least one mutation from (a) the reductase domain of cytochrome P450 BM3, wherein the reductase domain of cytochrome P450 BM3 is represented by SEQ ID NO: 1; or (b) a reductase domain having at least 95% sequence identity to SEQ ID NO:1; and wherein said mutation(s) result(s) in an increased cytochrome P450 monooxygenase activity as compared to a polypeptide comprising the reductase domain of SEQ ID NO: 1. The present invention also relates to a vector comprising the nucleic acid molecule of the invention and a host transformed with the vector. Furthermore, the invention relates to a method of producing a polypeptide comprising culturing the host of the invention as well as to a polypeptide encoded by the nucleic acid molecule of the invention or produced by the method of the invention. The present invention further relates to the use of the polypeptide of the invention in biotransformation or fine chemical synthesis, to an oligo- or polynucleotide which specifically hybridizes to the nucleic acid molecule of the invention as well as to a composition and to a kit.
    • 本发明涉及编码具有细胞色素P450单加氧酶活性的多肽的核酸分子,其中所述多肽包含通过至少一个突变从(a)细胞色素P450 BM3的还原酶结构域偏移的还原酶结构域,其中细胞色素的还原酶结构域 P450 BM3由SEQ ID NO:1表示; 或(b)与SEQ ID NO:1具有至少95%序列同一性的还原酶结构域; 并且其中与包含SEQ ID NO:1的还原酶结构域的多肽相比,增加的细胞色素P450单加氧酶活性的所述突变结果。本发明还涉及包含本发明的核酸分子的载体 和一个用矢量转换的主机。 此外,本发明涉及产生多肽的方法,其包括培养本发明的宿主以及由本发明的核酸分子编码或通过本发明的方法生产的多肽。 本发明还涉及本发明的多肽在生物转化或精细化学合成中与本发明的核酸分子以及组合物和试剂盒特异性杂交的寡核苷酸或多核苷酸的用途。
    • 3. 发明申请
    • ARCHAEON EXPRESSION SYSTEM
    • ARCHAEON表达系统
    • WO2004106527A1
    • 2004-12-09
    • PCT/EP2004/005936
    • 2004-06-02
    • B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AGSCHLEPER, ChristaJONUSCHEIT, MelanieECK, JürgenNIEHAUS, FrankALBERS, Sonja-VerenaFROELS, Sabrina
    • SCHLEPER, ChristaJONUSCHEIT, MelanieECK, JürgenNIEHAUS, FrankALBERS, Sonja-VerenaFROELS, Sabrina
    • C12N15/74
    • C12N15/74
    • The present invention relates to a sulfolobus expression vector comprising: (a) sulfolobus origin of replication; (b) the genes encoding the structural proteins and the site-specific integrase of SSVI, SSV2 or pSSVx, operatively linked to expression control sequences and a packaging signal; (c) one or more selectable marker gene(s), operatively linked to sulfolobus expression control sequences; and (d) a sulfolobus promoter followed 3' by a restriction enzyme recognition site or a multiple cloning site for insertion of a gene of interest and optionally a 3' regulatory element. Moreover, the present invention relates to a shuttle vector comprising the sequences of the expression vector of the invention and additional sequences for propagation and selection in E. coli, wherein the additional sequences comprise (a) an E.coli on of replication; and (b) a marker for selection in E.coli. Furthermore, the invention relates to host cells transformed with the expression vector as well as to a kit comprising a vector or a host cell of the present invention. Finally, the present application also relates to a method for generating infectious subviral particles.
    • 本发明涉及一种磺基蛇毒表达载体,其包含:(a)磺基链复制起点; (b)编码与表达控制序列和包装信号有效连接的SSVI,SSV2或pSSVx的结构蛋白和位点特异性整合酶的基因; (c)一个或多个选择性标记基因,其可操作地连接到子叶表达控制序列; 和(d)通过限制性酶识别位点或用于插入目的基因和任选的3'调节元件的多克隆位点的3'后的磺基叶酸启动子。 此外,本发明涉及包含本发明的表达载体的序列和在大肠杆菌中用于繁殖和选择的其它序列的穿梭载体,其中所述另外的序列包含(a)复制的大肠杆菌; 和(b)在大肠杆菌中选择的标记物。 此外,本发明涉及用表达载体转化的宿主细胞以及包含本发明的载体或宿主细胞的试剂盒。 最后,本申请还涉及产生感染性亚病毒颗粒的方法。
    • 4. 发明申请
    • PROTEASE FOR WOUND CONDITIONING AND SKIN CARE
    • 蛋白酶对伤口调理和皮肤护理
    • WO2010099955A1
    • 2010-09-10
    • PCT/EP2010/001328
    • 2010-03-03
    • B.R.I.A.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AGNIEHAUS, FrankECK, JürgenSCHULZE, Renate
    • NIEHAUS, FrankECK, JürgenSCHULZE, Renate
    • C12N9/64C07K16/40A61K38/43C12N15/62C12N5/10
    • C12N9/6408
    • We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds. Described is a nucleic acid molecule encoding a serine protease having the ability to cleave fibrin and casein which is (a) a nucleic acid molecule encoding the serine protease comprising or consisting of the amino acid sequence of SEQ ID NO: 4 as well as to nucleic acid molecules encoding precursors or fragments of said serine protease; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 3; (c) a nucleic acid molecule encoding a serine protease the amino acid sequence of which is at least 80 % identical to the amino acid sequence of (a), preferably at least 85 % identical, more preferably at least 90 % identical, and most preferred 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 80 % identical to the nucleotide sequence of (b), preferably at least 85 % identical, more preferably at least 90 % identical, and most preferred 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (b) or (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.
    • 我们已经通过分子克隆鉴定了来源于丝光绿蝇幼虫的蛋白酶,并且由于其活性可用于伤口清创,因此被称为清创酶。 描述了编码丝氨酸蛋白酶的核酸分子,所述丝氨酸蛋白酶具有切割纤维蛋白和酪蛋白的能力,所述纤维蛋白和酪蛋白是(a)编码包含SEQ ID NO:4的氨基酸序列或由SEQ ID NO:4的氨基酸序列组成的丝氨酸蛋白酶的核酸分子, 编码所述丝氨酸蛋白酶的前体或片段的酸分子; (b)包含SEQ ID NO:3的核苷酸序列或由其组成的核酸分子; (c)编码丝氨酸蛋白酶的核酸分子,其氨基酸序列与(a)的氨基酸序列至少80%相同,优选至少85%相同,更优选至少90%相同,且大多数 优选的95%相同; (d)包含与(b)的核苷酸序列至少80%相同,优选至少85%相同,更优选至少90%相同,并且最优选95%相同的核苷酸序列或由其组成的核酸分子, 相同; (e)相对于(b)或(d)的核酸分子简并的核酸分子; 或(f)对应于(a)至(d)中任一项的核酸分子的核酸分子,其中T被U取代。